Metabolic effects of pamidronate in patients with metastatic bone disease
1996

Effects of Pamidronate on Bone Metastases

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): J Vinholes, C-Y Guo, OP Purohit, R Eastell, RE Coleman

Primary Institution: University of Sheffield

Hypothesis

Pamidronate will effectively reduce bone resorption markers in patients with metastatic bone disease.

Conclusion

Pamidronate significantly reduces bone resorption markers and provides pain relief in patients with metastatic bone disease.

Supporting Evidence

  • Pamidronate induced a significant fall in bone resorption markers.
  • 70% of patients had increased deoxypyridinoline levels before treatment.
  • Biochemical responders had a mean reduction in pain score of about 30%.

Takeaway

Pamidronate helps people with cancer that has spread to their bones by reducing pain and lowering certain markers in the body that show how much bone is being broken down.

Methodology

Twenty patients received a single infusion of pamidronate and were evaluated at baseline, 2, 4, and 8 weeks after treatment, with various biochemical markers measured.

Potential Biases

Potential bias due to the lack of a control group and the subjective nature of pain assessment.

Limitations

The study had a small sample size and was limited to patients with specific types of bone metastases.

Participant Demographics

15 women with breast cancer, 3 men with prostate cancer, and 2 others; mean age 48 years.

Statistical Information

P-Value

p<0.017

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication